Trillium Therapeutics Inc. (TRIL)
Stock Price:
$18.71 USD
-1.42 (-7.05%)
Updated December 1, 4:00 PM EST - Market closed
After-hours: $18.75 +0.04 (0.21%) Dec 1, 7:58 PM
Key Info
| Market Cap |
1.84B |
| Revenue (ttm) |
94,656 |
| Net Income (ttm) |
-31.77M |
| Shares Out |
98.38M |
| EPS (ttm) |
-2.90 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
December 1 |
| Last Price |
$18.71 |
| Previous Close |
$20.13 |
| Change ($) |
-1.42 |
| Change (%) |
-7.05% |
| Day's Open |
20.54 |
| Day's Range |
18.66 - 20.71 |
| Day's Volume |
1,548,862 |
| 52-Week Range |
0.30 - 20.71 |
More Stats
| Market Cap |
1.84B |
| Enterprise Value |
1.82B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
98.38M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
-2.90 |
| FCF / Share |
-1.31 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
5.94M |
| Short Ratio |
4.78 |
| Short % of Float |
n/a |
| Beta |
1.88 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
19,445.65 |
| PB Ratio |
10.63 |
| Revenue |
94,656 |
| Operating Income |
-27.05M |
| Net Income |
-31.77M |
| Free Cash Flow |
-19.26M |
| Net Cash |
17.30M |
| Net Cash / Share |
0.18 |
| Gross Margin |
100.00% |
| Operating Margin |
-28,579.03% |
| Profit Margin |
-33,566.10% |
| FCF Margin |
-20,348.39% |
| ROA |
-19.01% |
| ROE |
-189.45% |
| ROIC |
-943.00% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (8)
| Buy |
8 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$20.71*
(10.69% upside)
Low
14.0
Current: $18.71
High
28.0
Target: 20.71
*Average 12-month USD price target from 7 stock analysts.
Financial Performance
Financial numbers in millions CAD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 0.12 | - | - | - | - | - | - |
| Gross Profit | 0.12 | - | - | - | - | - | - |
| Operating Income | -35.44 | -36.37 | -41.00 | -33.72 | -21.23 | -13.17 | -4.30 |
| Net Income | -41.62 | -32.87 | -45.09 | -31.73 | -14.73 | -12.88 | -4.29 |
| Shares Outstanding | 14.69 | 13.15 | 7.85 | 7.80 | 4.43 | 0.15 | - |
| Earnings Per Share | -1.65 | -2.35 | -4.61 | -4.06 | -2.22 | -3.06 | -3.16 |
| Operating Cash Flow | -24.91 | -30.46 | -27.04 | -22.85 | -18.30 | -7.45 | -2.48 |
| Capital Expenditures | -0.32 | -0.06 | -0.47 | -2.97 | -0.75 | -0.17 | -0.03 |
| Free Cash Flow | -25.23 | -30.52 | -27.51 | -25.82 | -19.05 | -7.62 | -2.52 |
| Cash & Equivalents | 22.67 | 33.39 | 64.91 | 50.47 | 86.77 | 26.17 | 32.98 |
| Total Debt | - | - | - | 0.19 | 0.27 | 0.28 | 0.34 |
| Net Cash / Debt | 22.67 | 33.39 | 64.91 | 50.28 | 86.50 | 25.88 | 32.64 |
| Assets | 25.41 | 40.78 | 74.92 | 66.62 | 90.04 | 28.19 | 35.09 |
| Liabilities | 25.58 | 10.19 | 12.56 | 8.50 | 4.24 | 3.88 | 1.18 |
| Book Value | -0.17 | 30.59 | 62.36 | 58.12 | 85.80 | 24.30 | 33.91 |
Numbers in millions CAD, except per-share numbers.
Company Details
| Full Name |
Trillium Therapeutics Inc. |
| Country |
Canada |
| CEO |
Jan Skvarka |
Stock Information
| Ticker Symbol |
TRIL |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: TRIL |
Description
Trillium Therapeutics, a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.